VTI: all 3 statistical targets hit, but the roadmap is not over yet
VTI is at week 8 of a buy trade with a breakeven stop and +8% gain from entry. All 3 statistical model targets were hit ahead of schedule — but the roadmap runs through week 10, with the final management window still ahead.
Vanguard Total World Stock ETF: week 8, two targets hit, final window approaching
The Vanguard Total World Stock ETF is at week 8 of a trade up 6%. Two of the 3 model targets have already been hit, the stop is at breakeven, and the next management window arrives at week 10. The signal is fading: this is a time for management, not reinforcement.
Vertex Pharmaceuticals: 10 weeks into a sell signal, but the decline stalls
Vertex Pharmaceuticals is in week 10 of a sell signal, but the last 4 weeks tell a story that contradicts the decline: buying volume, CMF turned positive, and MACD histogram converging toward zero.
Vertiv Holdings: sell signal at week 1, but +150% above the long-term average puts the brakes on
Vertiv Holdings receives a weekly sell signal in its first week. The bearish structure is confirmed, yet the stock trades 150% above its 200-week average: the quality band flags trading as not recommended, and the model advises caution before any short entry.
Valero Energy Corporation: coverage complete, the runner hits choppier waters
At week 21, Valero Energy has completed the model's coverage with a 38% gain. The 40% runner is still alive, but the technical picture signals cooling momentum: MACD histogram in negative territory, CMF near zero, mixed weekly pattern.
Vanguard Dividend Appreciation ETF: 3 targets hit, the roadmap continues
At week 8, all 3 statistical model targets have already been hit, but the management roadmap runs to week 10. Stop at breakeven: zero risk. Strength at 20, fading signal, ranked 160th out of 161.